维康药业(300878) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 195,738,788.54, representing a 6.50% increase compared to CNY 183,784,056.82 in the same period last year[5] - Net profit attributable to shareholders was CNY 27,526,041.93, up 20.10% from CNY 22,919,976.17 year-on-year[5] - Net profit for Q1 2023 reached CNY 28,017,798.79, representing a growth of 21.5% from CNY 23,128,425.85 in Q1 2022[19] - The total comprehensive income for the first quarter of 2023 was CNY 28,017,798.79, an increase from CNY 23,128,425.85 in the same period last year, representing a growth of approximately 21.5%[20] - The net profit attributable to the parent company was CNY 27,526,041.93, compared to CNY 22,919,976.17 in the previous year, marking an increase of about 20.2%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 13,486,613.08, a 273.94% increase from a negative CNY 7,753,792.32 in the previous year[5] - Cash inflows from operating activities totaled CNY 138,651,727.79, while cash outflows amounted to CNY 125,165,114.71, resulting in a net cash inflow of CNY 13,486,613.08[23] - The company reported cash and cash equivalents at the end of the period amounting to CNY 211,590,625.68, an increase from CNY 193,666,223.27 at the end of the previous period[23] - Cash received from government subsidies related to operating activities increased by 45.51% to CNY 3,993,821.22 from CNY 2,744,671.41 year-on-year[9] - The company raised CNY 88,240,496.00 through financing activities, with a net cash flow from financing activities of CNY 86,855,234.10[23] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,018,407,162.08, a 5.47% increase from CNY 1,913,773,127.42 at the end of the previous year[5] - Current liabilities totaled CNY 452,929,636.38, an increase of 9.7% from CNY 412,995,292.72 in the previous year[16] - The total liabilities increased to CNY 579,451,606.33, compared to CNY 502,254,330.46 in the previous year, showing a growth of 15.4%[16] - Long-term borrowings rose significantly to CNY 71,633,846.16, compared to CNY 33,393,350.16 in the same quarter last year, indicating a growth of 114.4%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,215[11] - Liu Zhongliang holds 60.89% of shares, amounting to 88,162,900 shares, while Liu Zhongjiao holds 6.82% with 9,872,030 shares[11] - The total number of restricted shares at the end of the period is 104,853,289, with 111,060 shares released during the period[12] - The total number of preferred shareholders is not applicable for this reporting period[12] Expenses and Costs - Total operating costs for Q1 2023 were CNY 165,096,759.61, up from CNY 162,915,922.80 in the same period last year, reflecting a slight increase of 1.3%[18] - Research and development expenses for Q1 2023 were CNY 8,841,656.30, up from CNY 7,808,286.33, reflecting a 13.2% increase year-over-year[19] - The company reported a significant increase in financial expenses, which rose to CNY 1,269,264.90, a 2018.35% increase compared to CNY 59,917.73 last year[9] Investment and Income - Investment income grew by 186.02% to CNY 5,959,695.88, compared to CNY 2,083,670.00 in the previous year[9] - The company reported an investment income of CNY 5,959,695.88, which is a substantial increase from CNY 2,083,670.00 in Q1 2022[19] Other Information - The company has no new product or technology developments mentioned in the reports[11][12][13] - There are no significant market expansion or acquisition strategies outlined in the reports[11][12][13] - The company has not provided specific future outlook or performance guidance in the available documents[11][12][13] - The company has not disclosed any other new strategies in the reports[11][12][13] - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[24]